Figure 19 is a forest plot depicting our meta-analysis on percent of patients achieving “response,” defined as at least 25% to 35% improvement on the Yale–Brown Obsessive Compulsive Scale (Y-BOCS). Two placebo controlled trials evaluated the use of olanzapine as augmentation to treat OCD and neither found a statistically significant effect. Five placebo controlled trials of quetiapine augmentation were pooled, results were not significant. Three placebo controlled trials of augmentation with risperidone were pooled, resulting in a statistically significant pooled estimate of the relative risk of responding of 3.92.

Figure 19OCD—responders improving 25–35% on Y-BOCS

From: Results

Cover of Off-Label Use of Atypical Antipsychotics: An Update
Off-Label Use of Atypical Antipsychotics: An Update [Internet].
Comparative Effectiveness Reviews, No. 43.
Maglione M, Maher AR, Hu J, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.